Current pharmacotherapies for atherosclerotic cardiovascular diseases
- 주제(키워드) Atherosclerotic cardiovascular diseases (ASCVD) , Pharmaceutical therapies , Lipid-lowering drugs , Anti-inflammatory therapies , Statin , Ezetimibe , PCSK9 inhibitor , Canakinumab , Methotrexate
- 주제(기타) Chemistry, Medicinal; Pharmacology & Pharmacy
- 설명문(일반) [Park, Jong-Gil] KRIBB, Biotherapeut Translat Res Ctr, 125 Gwahak Ro, Daejeon 34141, South Korea; [Oh, Goo Taeg] Ewha Womans Univ, Dept Life Sci, Natl Creat Initiat, Immune & Vasc Cell Network Res Ctr, 52 Ewhayeodae Gil, Seoul 120750, South Korea
- 등재 SCIE, SCOPUS, KCI등재
- 발행기관 PHARMACEUTICAL SOC KOREA
- 발행년도 2019
- URI http://www.dcollection.net/handler/ewha/000000159979
- 본문언어 영어
- Published As http://dx.doi.org/10.1007/s12272-019-01116-1
- PubMed https://pubmed.ncbi.nlm.nih.gov/30725249
- 저작권 이화여자대학교 논문은 저작권에 의해 보호받습니다.
초록/요약
Despite the introduction of statins for lowering LDL-C level, atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death and morbidity worldwide. Combination therapies with statin and other lipid-lowering drugs, including ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have unlocked additive benefits for treatment of ASCVD, but morbidity and mortality due to ASCVD remain high. New anti-inflammatory therapies have emerged for treatment and prevention of ASCVD to address these problems. Canakinumab neutralization of interleukin-1 beta (IL-1 beta) is the only verified therapy, and low-dose methotrexate holds promise due to its efficacy and safety for treatment of ASCVD. However, many agonistic and antagonistic candidates within inflammation pathways have failed to develop into useful drugs for ASCVD because of the complexity of the inflammatory process in atherosclerosis. In this review, we outline current and future pharmaceutical therapies for ASCVD in terms of lipid-modifying strategies and anti-inflammation treatments.
more